Bacteriophages and the Phage Therapy Revival: From Dudley Zoo to Pasteur Institute

Overview

The podcast delves into the world of bacteriophages, exploring how these friendly viruses could transform the treatment of bacterial infections and address the looming threat of antimicrobial resistance. It follows historical threads from the Eliava Institute in Tbilisi to the Pasteur Institute in Paris, and investigates contemporary efforts in the UK and Europe to bring phage therapy into clinical practice.

Key insights

• bacteriophages as targeted agents against bacterial pathogens
• historical pivots between phage research and antibiotic dominance
• real-world lab work from zoo animal samples to sequencing
• regulatory and clinical challenges shaping the future of phage therapy

Introduction to phages and the revival of phage therapy

The podcast introduces bacteriophages, viruses that infect bacteria, highlighting their potential to treat antibiotic resistant infections. It explains how phages are highly specific predators of bacteria, making them an attractive alternative or complement to conventional antibiotics. The host emphasizes the urgent need for new therapies as antibiotic resistance threatens modern medicine.

The science behind phage therapy

Phages work by infecting specific bacterial strains and multiplying inside them until the bacteria lyse. The discussion covers safety profiles, with researchers pointing to the natural presence of phages in human-associated bacteria and existing clinical evidence. The host notes that while phages have long been known, licensing and standardization remain barriers to widespread use, requiring robust clinical trials and careful safety evaluation.

Historical roots and geographic hubs

The podcast explores the Eliava Institute in Tbilisi, Georgia, where phage therapy was historically developed for military and public health use under the Soviet system. It contrasts this with the Pasteur Institute in Paris, where phage research flourished in the early 20th century and later faced discontinuation as antibiotics became dominant. The history section underscores how geopolitical divides affected access to phage research and regulation.

The zoo samples and the lab journey

The narrative moves to a field trip at Dudley Zoo, where researchers collect snow leopard poo to hunt for bacteriophages in animal gut microbiomes. The hosts detail how poo from diverse species can be a rich reservoir of phages and why exploring zoo animal microbiomes could uncover phages with therapeutic potential. The lab sequences and screens phages, using agar plates to observe plaque formation as a sign of viral activity against bacteria like E. coli.

UK clinicians, antimicrobial resistance, and regulatory landscape

The program features UK infectious disease professionals reflecting on the threat of antimicrobial resistance. They discuss the need for alternatives and the careful risk assessment required to bring phage therapy into standard practice. The conversation highlights ongoing regulatory reviews that could enable more personalized phage therapies while balancing safety, efficacy, and ethical considerations.

Phagos and the AI-driven platform future

The episode introduces Phagos, a Paris-based biotech startup aiming to create a platform for phage therapy production. The company envisions scalable manufacturing of phages, regulated similarly to antibiotics, paired with AI and automation to accelerate discovery, optimization, and quality control. The discussion covers the challenges of patenting phages versus phage production processes, and how synthetic or engineered phages might fit into a future therapeutic landscape.

Concluding perspectives

Across histories and continents, the podcast paints phage therapy as a field at a crossroads—where historical knowledge, modern regulation, and cutting-edge technology converge to potentially redefine how bacterial infections are treated in the 21st century.